Home > Pulmonology > ERS 2020 > COPD – The Beat Goes On > Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients

Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients

Presented By
Dr Jens Bräunlich, Kliniken Aurich-Emden-Norden, Germany
Conference
ERS 2020
According to a German study, nasal high-flow (NHF) therapy might be a valuable addition to the existing oxygen delivery devices, particularly in COPD patients that cannot tolerate a mask [1]. NHF is a promising novel oxygen delivery device that allows a high flow of a heated and humidified gas mixture, thereby promoting higher and more stable inspiratory oxygen fraction values and generating a positive airway pressure that can reduce the work of breathing and enhance patient comfort and tolerance [2]. Stable COPD patients could benefit from its application through a reduction of anatomical dead space and an improvement in mucociliary clearance in conducting airways. After the positive effects of a pilot study, Dr Jens Bräunlich (Kliniken Aurich-Emden-Norden, Germany) and his team compared NHF with non-invasive ventilation (NIV) in 102 patients with chronic hypercapnic COPD from 14 sites. The primary endpoint was pCO2 changes from baseline blood gas....


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on